These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9750532)

  • 1. [Trend in genetic medicine].
    Shoji Y; Mizushima Y
    Nihon Rinsho; 1998 Aug; 56(8):2186-95. PubMed ID: 9750532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
    Fattal E; Bochot A
    Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes.
    Fattal E; Couvreur P; Dubernet C
    Adv Drug Deliv Rev; 2004 Apr; 56(7):931-46. PubMed ID: 15066753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of delivery systems to improve target efficacy of oligonucleotides.
    Shoji Y; Nakashima H
    Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antisense oligonucleotide drug delivery systems.
    Weyermann J; Lochmann D; Zimmer A
    J Control Release; 2004 Dec; 100(3):411-23. PubMed ID: 15567506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular uptake and intracellular fate of antisense oligonucleotides.
    Thierry AR; Vives E; Richard JP; Prevot P; Martinand-Mari C; Robbins I; Lebleu B
    Curr Opin Mol Ther; 2003 Apr; 5(2):133-8. PubMed ID: 12772502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug delivery systems in gene therapy].
    Takakura Y
    Nihon Rinsho; 1998 Mar; 56(3):691-5. PubMed ID: 9549358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense inhibitors, ribozymes, and siRNAs.
    Thompson AJ; Patel K
    Clin Liver Dis; 2009 Aug; 13(3):375-90. PubMed ID: 19628155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The delivery of antisense therapeutics.
    Akhtar S; Hughes MD; Khan A; Bibby M; Hussain M; Nawaz Q; Double J; Sayyed P
    Adv Drug Deliv Rev; 2000 Oct; 44(1):3-21. PubMed ID: 11035194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entrapment of small molecules and nucleic acid-based drugs in liposomes.
    Fenske DB; Cullis PR
    Methods Enzymol; 2005; 391():7-40. PubMed ID: 15721372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation of cationic liposomes and its role in enhancing cellular uptake of antisense oligonucleotides].
    Chen HL; Liang WQ; Shao JB; Chen Z
    Yao Xue Xue Bao; 2004 Jan; 39(1):72-6. PubMed ID: 15127587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular delivery of antisense oligonucleotides.
    Lebedeva I; Benimetskaya L; Stein CA; Vilenchik M
    Eur J Pharm Biopharm; 2000 Jul; 50(1):101-19. PubMed ID: 10840195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis.
    Yang J; Zeng Y; Li Y; Song C; Zhu W; Guan H; Li X
    Eur J Pharm Sci; 2008 Dec; 35(5):427-34. PubMed ID: 18848882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleic acid aptamers as tools and drugs: recent developments.
    Rimmele M
    Chembiochem; 2003 Oct; 4(10):963-71. PubMed ID: 14523912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.